Jonathan Bernstein, MD

Bernstein also discussed other unmet needs in the field and how his center is working to address them.

Staying Up to Date on Urticaria, Mast Cell Disorders, with Jonathan Bernstein, MD

Angioedema can be a complication with inflammatory skin conditions such as urticaria and levies a significant burden on patients. Jonathan Bernstein, MD, adjunct professor, University of Cincinnati School of Medicine and past president of the American Academy of Allergy, Asthma, and Immunology (AAAAI) gave a talk on emerging treatment approaches for angioedema in patients with urticaria at the 2025 AAAAI/World Allergy Organization Joint Congress, February 28-March 3, in San Diego, California. Bernstein also serves as Chair of the Asthma Committee for the American College of Allergy Asthma and Immunology, and is on the Board of Directors of the WAO and Interasma.

“Patients with chronic urticaria… often times don't know where to go and how to receive effective treatment. Their journey can be burdensome, especially ones who don't respond well to treatment… [There are] a lot of wasted dollars and direct and indirect costs associated with this condition. So hopefully, we can shorten the duration of diagnosis and effective therapies by getting these patients in the hands of experts,” Bernstein told 

 spoke with Bernstein to learn more about unmet needs in the field, including a need for more clinician education and patient advocacy, which he is working to improve with the We CU advocacy group his center recently launched. He also discussed other emerging inflammatory skin diseases such as mast cell disorders, which he stressed can be complex for both clinicians and patients alike.

“We're trying to educate our colleagues about neuroimmunology and about the importance of looking at these patients more holistically and not just focused on, Do they have a positive tryptase or not? But you know, we definitely are seeing a whole new type of population in our offices, in our clinics, and these people are oftentimes pushed from one doctor to the next, and it's very difficult for them and very burdensome. So hopefully we'll start to have better their future options for them as well,” Bernstein said.

Bernstein's disclosures include Inspirotec and Ineos.

Bernstein J. Emerging Treatment Approaches to Hives, Itch, and Angioedema. Presented at: 2025 AAAAI/WAO Joint Congress, February 28-March 3.

Videos

Staying Up-to-Date on Urticaria, Mast Cell Disorders, with Jonathan Bernstein, MD

 Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD

Angioedema is a complication that has a significant burden on patients with inflammatory skin conditions such as urticaria. While research is ongoing in the field to better treat angioedema, unmet needs in its management remain.

Jonathan Bernstein, MD, adjunct professor, University of Cincinnati School of Medicine and past president of the American Academy of Allergy, Asthma, and Immunology (AAAAI) is giving a talk on emerging treatment approaches for angioedema in patients with urticaria at the 2025 AAAAI/World Allergy Organization Joint Congress, February 28-March 3, in San Diego, California.

“I think that's really the biggest thing that's confronting us, is to get clinicians understand the spectrum of angioedema and to make sure that they aren't skipping steps and going from inexpensive antihistamines to extremely expensive drugs that are targeted towards hereditary angioedema,” Bernstein told 

 spoke with Bernstein to learn more about unmet needs in patients with angioedema and urticaria, including making appropriate decisions and implementing physician education to improve this. He also discussed progress in research in the space, and current research adding to the field’s understanding of the disease, including mast cells mechanisms.

“We're learning more about mast cell biology and activation, which is really important in terms of drug development. So, we'll see how everything plays out in terms of, you know, looking at these more difficult to treat patients with chronic urticaria, and how these drugs work, but I think that we're going to see a significant benefit for patients who don't respond well to antihistamines or omalizumab in responding to some of these other alternative, mechanistic, mechanistically driven therapies,” Bernstein said.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Jonathan Bernstein, MD

Articles